O
OnKure Therapeutics, Inc. (OKUR)
NGM – Real vaqt narxi. Valyuta: USD
4.50
+0.28 (6.64%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.53
+0.03 (0.67%)
Bozordan keyin: Jun 26, 2026, 7:43 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
4.50
+0.28 (6.64%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.53
+0.03 (0.67%)
Bozordan keyin: Jun 26, 2026, 7:43 PM EDT
OnKure Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton va boshqa kasalliklarning biologik tasdiqlangan omillarini nishonga oluvchi aniq dorilarni kashf qilish va ishlab chiqishga qaratilgan. Uning asosiy mahsulot nomzodi OKI-219 ni o'z ichiga oladi, bu fosfoinozitid 3-kinaza alfa (PI3Kα) ning selektiv ingibitori bo'lib, H1047R mutatsiyasiga ega bo'lib, u ko'krak bezi saratoni kabi qattiq o'smalarni davolash uchun 1-bosqich klinik sinovdan o'tmoqda. Kompaniya 2011 yilda tashkil etilgan va shtab-kvartirasi Kolorado shtatining Bouldr shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dylan Hartley Ph.D. | Chief Scientific Officer |
| Dr. Isaac Manke Ph.D. | Senior VP of Business Development & Director |
| Dr. James Blake Ph.D. | Senior Vice President of Computational Drug Discovery |
| Dr. Kevin S. Litwiler Ph.D. | Senior Vice President of DMPK & Clinical Pharmacology |
| Dr. Mark L. Boys Ph.D. | Senior Vice President of Discovery Chemistry |
| Dr. Nicholas A. Saccomano Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-05 | S-8 | okur-20260604.htm |
| 2026-06-04 | 8-K | okur-20260603.htm |
| 2026-05-05 | 8-K | okur-20260505.htm |
| 2026-05-05 | 10-Q | okur-20260331.htm |
| 2026-04-30 | CORRESP | filename1.htm |
| 2026-04-24 | S-3 | d122209ds3.htm |
| 2026-04-21 | DEFA14A | ny20066577x2_defa14a.htm |
| 2026-04-21 | DEF 14A | ny20066577x1_def14a.htm |
| 2026-04-21 | ARS | okur_ars_2025.pdf |
| 2026-03-30 | 8-K | d910791d8k.htm |
| President, CEO & Director |
| Dr. Samuel Agresta M.D., M.P.H. | Chief Medical Officer |
| Mr. Jason A. Leverone CPA | Chief Financial Officer |
| Mr. Rogan P. Nunn J.D. | General Counsel & Secretary |
| Ms. Roberta Alton | Senior Vice President of Clinical Operations |